Fig. 6

Antitumor acitivity of crizotinib combined with anlotinib in H3122CR-derived xenograft model. A Schematic diagram of anlotinib reversing crizotinib resistance by inhibition of angiogenesis via JAK2/STAT3-CCL20-VEGFA/IL6 axis; B Inhibition effect of anlotinib combined with crizotinib on H3122CR compared with anlotinib or crizotinib monotherapy; C Timeline of the treatment in mice; D Measurements of subcutaneous tumor volumes in the control, crizotinib monotherapy, anlotinib monotherapy, and crizotinib combined with anlotinib groups (n = 24); E Tumors were obtained after mice were sacrificed on Day 26; F Measurement of tumor weight at the end of the experiment; G Body weight growth curves of nude mice during the treatment; H Body weight minus tumor weight was analyzed at the end of the experiment. *p < 0.05, **p < 0.01, ***p < 0.001, ns not significant